Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update
FREMONT, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today
View HTML
Toggle Summary Zosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicine's Pain Management Journal
FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA
Confirmation of previously announced design of Long-term Safety Study Recently completed ZOTRIP study acknowledged sufficient for NDA filing CMC development strategy confirmed adequate for registration FREMONT, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc.
View HTML
Toggle Summary Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
FREMONT, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, today announced that it has approved
View HTML
Toggle Summary Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom
FREMONT, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, presented additional data
View HTML
Toggle Summary Zosano to Present Migraine Data at Three Industry-Leading Conferences
Late-Breaking Oral and Oral Presentations to feature M207 Acute Migraine Therapy Zotrip Pivotal Trial Data Selected by Headache Society and Drug Delivery Meetings FREMONT, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a specialty pharmaceutical company that
View HTML
Toggle Summary Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes
Pivotal trial of M207 meets co-primary endpoints to establish fast and durable pain relief $29.3 million follow-on offering of common stock provides funding for initiating required safety study and meeting pre-commercialization CMC/ manufacturing criteria Zosano names John P.
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update
FREMONT, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that it will host a conference call
View HTML
Toggle Summary Zosano Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Over-Allotment Option
FREMONT, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the closing of
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the pricing of
View HTML